Cleveland Clinic | Strategic Alliance Partners

October 15, 2015

The IMA901 multipeptide vaccine added to sunitinib failed to improve outcomes versus sunitinib alone as first-line therapy for advanced/metastatic renal cell carcinoma.

October 07, 2015

Aziz Nazha, MD, hematologist, Leukemia Program at the Cleveland Clinic, Taussig Cancer Institute, discusses results of a mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).

September 18, 2015

Hetty Carraway, MD, Hematology and Oncology, Cleveland Clinic, discusses combination epigenetic therapies including aza-nucleosides and histone deacetylase inhibitors, as well as immunomodulatory therapies, such as lenalidomide for the treatment of myelodysplastic syndromes (MDS).

September 16, 2015

Titrating dose levels of axitinib (Inlyta) improved response rates and extended overall survival by 12.3 months in patients with metastatic renal cell carcinoma.

September 09, 2015

Davendra Sohal, MD, MPH, oncologist and Director of the Clinical Genomics Program at the Cleveland Clinic Taussig Cancer Institute, discusses the feasibility of standardizing genomic profiling and apply precision medicine techniques.

September 04, 2015

James Stevenson, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute (TCI), discusses the impact of a stage IV non-small-cell lung cancer (NSCLC) care pathway on front-line and maintenance chemotherapy.

September 02, 2015

Alberto Montero, MD Staff Physician in the Department of Solid Tumor Oncology, Cleveland Clinic, discusses reducing readmission rates for oncology patients.

September 01, 2015

OncLive today announced it is teaming up with Cleveland Clinic, ranked a top-five hospital by U.S. News & World Report, to provide breaking news and information about the hospital's pioneering research and care for cancer patients. Editorial and marketing groups within OncLive, which provides oncologists resources and information they need to deliver the best care for their patients, will focus on many cancer-related programs and initiatives at Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education.

June 23, 2015

Marc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced BRAF-mutated or BRAF wild-type melanoma.

June 15, 2015

Alok Khorana, MD, medical oncologist, Cleveland Clinic, discusses blood clot risk and treatment for patients with cancer.

June 12, 2015

With bipartisan support, legislation aimed at reducing the high copays for self-injectable and oral cancer drugs was introduced in the House and Senate.

April 01, 2015

Jorge A. Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the challenges with immunotherapy in prostate cancer.

March 24, 2015

Alok A. Khorana, MD, specializes in predictive factors in gastrointestinal oncology and in cancer-associated thrombosis at the Cleveland Clinic. He provided insight on gastric cancer research in an interview with OncLive.

January 08, 2015

Anjali Advani, MD ,staff physician, Department of Hematologic Oncology and Blood Disorders, Director, Inpatient Leukemia Program, Taussig Cancer Institute, associate professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, compares inotuzumab ozogamicin, a CD22 monoclonal antibody, to blinatumomab, a CD19 bi-specific anti-CD19/CD3 antibody for the treatment of acute lymphoblastic leukemia (ALL).

October 13, 2014

Rini, who is a professor at the Cleveland Clinic Lerner College of Medicine in addition to holding several posts at the Case Comprehensive Cancer Center, discussed broad issues in antiangiogenic research in this interview with OncologyLive.

October 07, 2014

While biomarker-based tools designed to guide the diagnosis and treatment of prostate cancer are emerging at an extraordinarily rapid rate, they are not exploding in the same practice-changing way in all genitourinary cancers.

August 05, 2014

Halle Moore, MD, medical oncologist, Cleveland Clinic, discusses the results of the phase III POEMS study, which was presented at the 2014 ASCO Annual Meeting.

May 07, 2014

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).

April 29, 2014

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.

April 14, 2014

Robert Dreicer, MD, MS, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer.